Literature DB >> 19630074

Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis.

Aslaug R Lorentzen1, Tom H Karlsen, Marita Olsson, Cathrine Smestad, Inger-Lise Mero, Bente Woldseth, Ji-Yao Sun, David Senitzer, Elisabeth G Celius, Erik Thorsby, Anne Spurkland, Benedicte A Lie, Hanne F Harbo.   

Abstract

OBJECTIVE: Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system. A human leukocyte antigen (HLA) class II association is well established (DRB1*1501-DQB1*0602), but more recently HLA class II-independent associations with HLA class I variants have also been reported. The HLA class I (HLA-A, -B, -C) molecules serve as ligands for both T-cell receptors and killer immunoglobulin-like receptors (KIRs). We investigated the HLA class I alleles defined by their KIR binding motifs and the KIR genes to evaluate whether these genes could influence MS susceptibility or severity, alone or in combination.
METHODS: We typed Norwegian MS patients (n = 631) and controls (n = 555) for HLA-A, -B, -C and -DRB1 alleles as well as the presence or absence of genes encoding inhibitory (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3) and activating (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DL4, KIR2DS4, KIR2DS5, KIR3DS1) KIRs.
RESULTS: The frequency of the HLA-Bw4 specificity, which is the ligand for the inhibitory KIR3DL1, was significantly reduced in MS patients as compared with controls (41.4% vs 55.1%, p(uncorrected (uc)) = 4.6 x 10(-6)). Also after stratifying for known HLA class II associations, the HLA-Bw4 association was seen (p(uc) = 0.002). No significant differences in gene carrier frequencies of inhibitory and activating KIRs were observed. However, our data indicate that MS patients who carry the activating KIR2DS2 and the inhibitory KIR2DL2 genes have more severe disease than patients not carrying these genes.
INTERPRETATION: Carriage of the ligand of the inhibitory KIR3DL1 receptor, HLA-Bw4, was found to protect against MS in an HLA-DRB1 independent manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630074     DOI: 10.1002/ana.21695

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 2.  Multiple sclerosis genetics--is the glass half full, or half empty?

Authors:  Jorge R Oksenberg; Sergio E Baranzini
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

Review 3.  The genetics of multiple sclerosis: an up-to-date review.

Authors:  Pierre-Antoine Gourraud; Hanne F Harbo; Stephen L Hauser; Sergio E Baranzini
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

4.  Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.

Authors:  Suliman Y Alomar; Afrah Alkhuriji; Paul Trayhyrn; Abdulkarim Alhetheel; Abdullah Al-Jurayyan; Lamjed Mansour
Journal:  Immunogenetics       Date:  2016-09-15       Impact factor: 2.846

5.  The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas.

Authors:  Julia D Rempel; Kim Hawkins; Erin Lande; Peter Nickerson
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

6.  Contribution of functional KIR3DL1 to ankylosing spondylitis.

Authors:  Ivan V Zvyagin; Ilgar Z Mamedov; Olga V Britanova; Dmitriy B Staroverov; Evgeni L Nasonov; Anna G Bochkova; Anna V Chkalina; Alexei A Kotlobay; Dmitriy O Korostin; Denis V Rebrikov; Sergey Lukyanov; Yuri B Lebedev; Dmitriy M Chudakov
Journal:  Cell Mol Immunol       Date:  2010-09-06       Impact factor: 11.530

7.  Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis.

Authors:  Hanne F Harbo; Noriko Isobe; Pål Berg-Hansen; Steffan D Bos; Stacy J Caillier; Marte W Gustavsen; Inger-Lise Mero; Elisabeth Gulowsen Celius; Stephen L Hauser; Jorge R Oksenberg; Pierre-Antoine Gourraud
Journal:  Mult Scler       Date:  2013-10-07       Impact factor: 6.312

8.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

9.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

10.  Multiple sclerosis: major histocompatibility complexity and antigen presentation.

Authors:  Sreeram V Ramagopalan; George C Ebers
Journal:  Genome Med       Date:  2009-11-06       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.